Pivotal Trial Shows TransCon CNP Delivers Sustained 2-Year Growth Gains in Achondroplasia
ASND sits 56% above its 52-week low of $150.89.
Summary
Ascendis Pharma announced new 2-year data from its pivotal ApproaCH trial for TransCon CNP (YUVIWEL) in children with achondroplasia aged ≥5 years. The data demonstrated pronounced and sustained gains in annualized growth velocity and improvements in height Z-scores, alongside a consistent safety profile. This positive long-term clinical validation reinforces the efficacy and safety of YUVIWEL, which received FDA approval in February 2026. The strong data could enhance physician confidence and adoption, strengthening the drug's market position. Investors will now watch for the European Medicines Agency's regulatory decision, anticipated in the fourth quarter of 2026.
At the time of this announcement, ASND was trading at $235.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.7B. The 52-week trading range was $150.89 to $250.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.